S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IBRX · ImmunityBio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$8.63
-0.15
(-1.71%)
● At close: October 21 at 4:00:00 PM EDT
$8.59
-0.05
(-0.58%)
Overnight:
11:47:06 PM EDT
DAY'S RANGE
$8.63
$8.32
$8.98
52-WEEK RANGE
$8.63
$1.95
$12.43
What's happening
- IBRX is down 1.71% today, trading at $8.63. — Live quote
- Volume today (652,643) is well below its 3-month average of 11,691,590. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.22 actual vs. $-0.09 estimated (-139.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 5
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IBRX
+342.93%
vs S&P 500
+330.15%
1-YEAR RETURN
IBRX
+257.96%
vs S&P 500
+243.40%
6-MONTH RETURN
IBRX
+20.97%
3-MONTH RETURN
IBRX
+8.67%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.22
Est. $-0.09
MISS -139.7%
2026-04-26 (Q1 2026)
$-0.08
Est. $-0.07
MISS -12.0%
2026-01-26 (Q4 2025)
$-0.06
Est. $-0.10
BEAT +37.4%
2025-10-26 (Q3 2025)
$-0.07
Est. $-0.11
BEAT +36.5%
Valuation Measures & Ratios
Enterprise Value4$10.49B
Forward P/E5—
PEG Ratio6-0.09
Price / Sales (TTM1)56.57
Price / Book75.04
EV4 / Revenue63.29
EV4 / EBITDA—
Profit Margin-598.56%
Operating Margin-151.88%
Return on Equity (ROE8)-193.29%
Return on Assets (ROA9)-172.88%
Avg Volume (3M)11,691,590
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $9.17B | $7.80B | $2.35B | $2.44B | $2.60B |
| P/E | -8.96 | -8.46 | -6.27 | -5.51 | -5.37 |
| Price/Sales | 59.56 | 65.45 | 29.02 | 48.68 | 109.54 |
| Price/Book | -8.76 | -8.97 | -4.49 | -4.27 | -4.39 |
| EV/Revenue | 59.07 | 63.73 | 28.28 | 45.94 | 106.98 |
| EV/EBITDA | -37.61 | -31.00 | -8.98 | — | — |
| ROE | 97.74% | 106.00% | 71.56% | 77.53% | 81.84% |
| ROA | -162.76% | -142.62% | -72.29% | -110.05% | -159.35% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short124,092,202
Change from Prior Settlement-1.05%
% of Float—
Days to Cover (Short Ratio)8.88
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 93.9% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +258.0%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -598.6%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IBRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.2M | $44.2M | $32.1M | $26.4M | $16.5M | $6.1M | $1.0M | $40.0K |
| Operating income | -$61.7M | -$69.8M | -$55.6M | -$71.3M | -$64.4M | -$80.3M | -$99.3M | -$95.2M |
| Net income | -$230.4M | -$632.8M | -$67.3M | -$92.6M | -$129.6M | -$85.7M | -$134.6M | -$134.1M |
| EPS (diluted) | $-0.22 | $-0.62 | $-0.07 | $-0.10 | $-0.15 | $-0.14 | $-0.20 | $-0.20 |
| EPS (basic) | $-0.22 | $-0.62 | $-0.07 | $-0.10 | $-0.15 | $-0.12 | $-0.20 | $-0.20 |
| Operating margin | -$120 | -$158 | -$174 | -$270 | -$390 | -$1.3K | -$9.5K | -$238.0K |
| Net margin | -$450 | -$1.4K | -$210 | -$350 | -$785 | -$1.4K | -$12.9K | -$335.3K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $628.5M | $646.6M | $501.9M | $519.0M | $402.1M | $303.8M | $382.9M | $364.6M |
| Total liabilities | $1.67B | $1.52B | $1.00B | $1.04B | $971.9M | $894.2M | $871.1M | $1.11B |
| Stockholders' equity | -$1.05B | -$870.0M | -$500.5M | -$524.3M | -$570.7M | -$591.4M | -$489.1M | -$745.1M |
| Total current assets | $439.0M | $453.0M | $314.9M | $329.5M | $208.1M | $109.2M | $184.6M | $163.2M |
| Total current liabilities | $76.7M | $68.0M | $61.8M | $57.1M | $50.6M | $49.2M | $54.9M | $61.0M |
| Cash & equivalents | $75.7M | $205.2M | $88.3M | $60.2M | $137.7M | $60.7M | $143.4M | $112.0M |
| Marketable securities (current) | $281.7M | $175.7M | $154.5M | $197.6M | $16.0M | $931.0K | $6.4M | $18.4M |
| Accounts receivable | $53.5M | $43.3M | $42.6M | $32.0M | $22.1M | $17.0M | $2.4M | $4.2M |
| Inventory | $1.9M | $547.0K | $910.0K | $6.7M | $6.6M | $8.4M | $8.3M | $2.0M |
| Other current assets | — | $3.0M | $2.1M | $2.5M | $1.6M | $2.4M | $1.3M | $1.4M |
| Marketable securities (non-current) | — | — | — | — | — | — | $0 | $0 |
| Property, plant & equipment | $114.2M | $112.8M | $114.3M | $129.6M | $133.0M | $135.3M | $137.1M | $139.3M |
| Goodwill | — | $910.0K | $910.0K | $910.0K | $910.0K | $910.0K | $910.0K | $910.0K |
| Intangible assets | — | $11.9M | $13.0M | $13.5M | $13.5M | $14.0M | $14.5M | $15.0M |
| Other non-current assets | — | — | — | — | — | — | $4.8M | $3.6M |
| Accounts payable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | $48.2M | $46.8M | $43.6M | $35.7M | $27.9M | $40.6M | $43.6M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $510.0K | $472.0K | $424.0K | $702.0K | $710.0K | $370.0K | $319.0K | $705.0K |
| Common stock & paid-in capital | $105.0K | $104.0K | $101.0K | $98.0K | $91.0K | $85.0K | $85.0K | $70.0K |
| Retained earnings | -$4.59B | -$4.36B | -$3.73B | -$3.66B | -$3.60B | -$3.50B | -$3.38B | -$3.32B |
| Accumulated other comprehensive income (loss) | $27.3M | $27.5M | $29.0M | $5.0M | $12.6M | $20.0M | $1.2M | $103.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$66.5M | -$75.4M | -$70.4M | -$68.9M | -$79.7M | -$85.9M | -$85.1M | -$98.8M |
| Investing cash flow | -$107.5M | -$31.6M | $43.6M | -$181.4M | -$16.1M | $4.1M | $9.8M | $65.0M |
| Financing cash flow | $44.4M | $223.9M | $54.9M | $173.5M | $172.8M | -$982.0K | $106.9M | $15.6M |
| Free cash flow | -$70.0M | -$77.1M | -$71.3M | -$69.6M | -$80.8M | -$87.0M | -$87.3M | -$101.6M |
| Capital expenditures | $3.5M | $1.8M | $903.0K | $741.0K | $1.1M | $1.1M | $2.1M | $2.8M |
| Depreciation & amortization | $4.4M | $4.4M | $3.9M | $4.0M | $3.9M | $3.8M | $4.1M | $4.5M |
| Share-based compensation | $8.5M | $8.2M | $8.7M | $8.9M | $9.6M | $9.5M | $9.0M | $7.5M |
| Deferred income taxes | — | — | -$139.0K | — | — | — | $0 | — |
| Change in accounts receivable | $10.2M | $700.0K | $10.6M | $9.9M | $5.1M | $14.7M | -$1.8M | $3.1M |
| Change in inventory | -$1.0M | $5.0M | $7.9M | $63.0K | -$1.8M | $172.0K | $6.3M | $147.0K |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $164.2M | $139.1M | $45.6M | $180.6M | $15.1M | $100.0K | $6.1M | $0 |
| Sales/maturities of investments | $40.3M | $79.4M | $59.5M | $0 | $0 | $5.3M | $18.0M | $49.5M |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $319.0K | $7.0M | $590.0K | $151.0K | $322.0K | $1.2M | $803.0K | $299.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K | $934.0K |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| EPS (basic) | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 |
| Operating margin | -$226 | -$2.3K | -$58.2K | -$146.4K | -$35.4K |
| Net margin | -$310 | -$2.8K | -$93.8K | -$173.6K | -$37.1K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Total liabilities | $1.00B | $871.1M | $1.09B | $812.2M | $712.8M |
| Stockholders' equity | -$500.5M | -$489.1M | -$587.0M | -$447.3M | -$242.2M |
| Total current assets | $314.9M | $184.6M | $294.1M | $140.6M | $334.3M |
| Total current liabilities | $61.8M | $54.9M | $58.3M | $500.9M | $369.0M |
| Cash & equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Marketable securities (current) | $154.5M | $6.4M | $1.0M | $2.5M | $136.0M |
| Accounts receivable | $42.6M | $2.4M | $0 | — | — |
| Inventory | $910.0K | $8.3M | $0 | — | — |
| Other current assets | $2.1M | $1.3M | $1.5M | $2.0M | $3.0M |
| Marketable securities (non-current) | — | $0 | $891.0K | $840.0K | $822.0K |
| Property, plant & equipment | $114.3M | $137.1M | $146.1M | $143.7M | $82.9M |
| Goodwill | $910.0K | $910.0K | — | — | — |
| Intangible assets | $13.0M | $14.5M | $16.6M | $18.6M | — |
| Other non-current assets | — | $4.8M | $2.9M | $4.9M | $6.8M |
| Accounts payable | — | — | — | $21.0M | $11.4M |
| Accrued liabilities | $46.8M | $40.6M | $42.7M | $41.8M | $51.4M |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | $424.0K | $319.0K | $1.1M | $457.0K | $411.0K |
| Common stock & paid-in capital | $101.0K | $85.0K | $67.0K | $42.0K | $40.0K |
| Retained earnings | -$3.73B | -$3.38B | -$2.96B | -$2.38B | -$1.96B |
| Accumulated other comprehensive income (loss) | $29.0M | $1.2M | $10.0K | $183.0K | $4.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Investing cash flow | -$149.8M | -$12.2M | -$30.5M | $27.3M | -$84.9M |
| Financing cash flow | $400.2M | $281.6M | $558.3M | $233.6M | $505.4M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Capital expenditures | $3.8M | $6.9M | $30.6M | $78.2M | $33.6M |
| Depreciation & amortization | $15.5M | $17.6M | $18.5M | $18.3M | $14.2M |
| Share-based compensation | $36.8M | $34.4M | $49.2M | $40.2M | $57.2M |
| Deferred income taxes | -$139.0K | $0 | -$14.0K | -$4.0K | -$8.0K |
| Change in accounts receivable | $40.2M | $2.4M | $0 | $0 | — |
| Change in inventory | $6.3M | $8.3M | $0 | $0 | — |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $241.4M | $140.2M | $10.4M | $34.3M | — |
| Sales/maturities of investments | $64.9M | $115.6M | $10.1M | $128.2M | $56.2M |
| Share repurchases | — | — | — | — | $0 |
| Tax withholding on stock comp | $2.3M | $5.5M | $3.4M | $616.0K | $4.1M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IBRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers16.1%
Shares Outstanding1,050,070,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 34,083,262 | $298.4M | 3.25% | +29.4% | 2026-08-07 |
| State Street Corp | 21,398,438 | $187.3M | 2.04% | +20.8% | 2026-08-07 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 17,863,911 | $156.4M | 1.70% | +9.4% | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 15,691,579 | $137.4M | 1.49% | +3.7% | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 11,551,019 | $101.1M | 1.10% | -8.1% | 2026-08-14 |
| TWO SIGMA INVESTMENTS, LP | 11,097,106 | $97.2M | 1.06% | +153.0% | 2026-08-07 |
| GEODE CAPITAL MANAGEMENT, LLC | 9,847,896 | $86.2M | 0.94% | +22.6% | 2026-08-12 |
| MILLENNIUM MANAGEMENT LLC | 5,579,793 | $48.9M | 0.53% | +292.9% | 2026-08-14 |
| Northern Trust Corp | 3,565,248 | $31.2M | 0.34% | +42.3% | 2026-08-12 |
| Morgan Stanley | 3,432,678 | $30.1M | 0.33% | -14.6% | 2026-08-11 |
| Goldman Sachs Group Inc | 3,234,277 | $28.3M | 0.31% | -0.1% | 2026-08-14 |
| UBS Group AG | 3,195,728 | $28.0M | 0.30% | +8.5% | 2026-08-13 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,888,607 | $25.3M | 0.28% | +16.6% | 2026-08-14 |
| Woodline Partners LP | 2,500,189 | $21.9M | 0.24% | -27.5% | 2026-08-14 |
| SEB Asset Management AB | 2,447,150 | $21.4M | 0.23% | +0.0% | 2026-08-04 |
| VANGUARD FIDUCIARY TRUST CO | 2,412,338 | $21.1M | 0.23% | +13.6% | 2026-06-30 |
| Bank Of America Corp /De/ | 2,184,489 | $19.1M | 0.21% | -10.8% | 2026-08-14 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1,721,902 | $15.1M | 0.16% | -41.2% | 2026-08-14 |
| Federated Hermes, Inc. | 1,713,200 | $15.0M | 0.16% | +23.6% | 2026-08-12 |
| Royal Bank Of Canada | 1,542,717 | $13.5M | 0.15% | +3.8% | 2026-08-13 |
| Jpmorgan Chase & Co | 1,450,180 | $12.9M | 0.14% | -2.6% | 2026-08-12 |
| Bank of New York Mellon Corp | 1,314,760 | $11.5M | 0.13% | +58.1% | 2026-08-06 |
| FIRST TRUST ADVISORS LP | 1,214,667 | $10.6M | 0.12% | +0.0% | 2026-08-11 |
| Cetera Investment Advisers | 1,140,476 | $10.0M | 0.11% | +20.5% | 2026-08-12 |
| Sound Capital Solutions LLC | 1,120,808 | $9.8M | 0.11% | +0.0% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-10 to 2026-10-05
Recent transactions
- Insiders have net sold 541,499 shares over the last 182 days, across 0 purchases and 8 sales.
- Most recent: Simon Barry J. (Director) — Open market sale of 25,000 shares on 2026-10-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)541,499 sh(8 txns)
Net Shares-541,499
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Simon Barry J. | Director | Open market sale | 2026-10-05 | 25,000 |
| Cohen Cheryl | Director | Option exercise | 2026-10-02 | 55,979 |
| Selecky Christobel | Director | Option exercise | 2026-07-01 | 35,064 |
| SOON-SHIONG PATRICK | See remarks | Derivative conversion | 2026-03-31 | 4,606,596 |
| Sachs David C. | Chief Financial Officer | Option exercise | 2026-02-22 | 40,650 |
| LAUER REGAN J | Chief Accounting Officer | Option exercise | 2026-02-22 | 4,065 |
| Adcock Richard | CEO & President | Option exercise | 2026-02-22 | 152,439 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | Director | Open market sale | 25,000 | $10.75 |
| 2026-10-02 | Cohen Cheryl | Director | Option exercise | 55,979 | $2.98 |
| 2026-10-02 | Cohen Cheryl | Director | Open market sale | 81,056 | $10.50 |
| 2026-07-02 | Cohen Cheryl | Director | Option exercise | 55,979 | $2.98 |
| 2026-07-02 | Cohen Cheryl | Director | Open market sale | 131,210 | $9.50 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise | 35,064 | $2.98 |
| 2026-07-01 | Selecky Christobel | Director | Option exercise | 124,414 | $2.99 |
| 2026-07-01 | Selecky Christobel | Director | Open market sale | 159,478 | $9.02 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise | 700 | $2.98 |
| 2026-06-30 | Selecky Christobel | Director | Option exercise | 300 | $2.99 |
| 2026-06-30 | Selecky Christobel | Director | Open market sale | 1,000 | $9.00 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise | 32,173 | $2.98 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise | 33,549 | $2.99 |
| 2026-06-29 | Selecky Christobel | Director | Option exercise | 30,000 | $2.84 |
| 2026-06-29 | Selecky Christobel | Director | Open market sale | 95,722 | $9.01 |
| 2026-06-24 | Simon Barry J. | Director | Open market sale | 25,000 | $7.88 |
| 2026-06-04 | Simon Barry J. | Director | Open market sale | 23,033 | $7.18 |
| 2026-03-31 | SOON-SHIONG PATRICK | See remarks | Derivative conversion | 4,606,596 | $5.43 |
| 2026-02-24 | Simon Barry J. | Director | Open market sale | 75,000 | $12.01 |
| 2026-02-23 | Selecky Christobel | Director | Option exercise | 25,000 | $2.98 |
| 2026-02-23 | Selecky Christobel | Director | Open market sale | 25,000 | $10.00 |
| 2026-02-23 | Simon Barry J. | Director | Open market sale | 165,000 | $10.25 |
| 2026-02-22 | Sachs David C. | Chief Financial Officer | Option exercise | 40,650 | $0.00 |
| 2026-02-22 | Sachs David C. | Chief Financial Officer | Tax withholding | 20,682 | $8.70 |
| 2026-02-22 | SOON-SHIONG PATRICK | See remarks | Option exercise | 114,329 | $0.00 |
| 2026-02-22 | SOON-SHIONG PATRICK | See remarks | Tax withholding | 58,170 | $8.70 |
| 2026-02-22 | LAUER REGAN J | Chief Accounting Officer | Option exercise | 4,065 | $0.00 |
| 2026-02-22 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 1,673 | $8.70 |
| 2026-02-22 | Adcock Richard | CEO & President | Option exercise | 152,439 | $0.00 |
| 2026-02-22 | Adcock Richard | CEO & President | Tax withholding | 77,560 | $8.70 |
| 2026-02-22 | Simon Barry J. | Director | Option exercise | 15,243 | $0.00 |
| 2026-02-22 | Simon Barry J. | Director | Tax withholding | 6,026 | $8.70 |
| 2026-02-20 | Simon Barry J. | Director | Open market sale | 10,000 | $9.25 |
| 2026-02-10 | SOON-SHIONG PATRICK | See remarks | Option exercise | 274,122 | $0.00 |
| 2026-02-10 | SOON-SHIONG PATRICK | See remarks | Tax withholding | 118,560 | $6.93 |
| 2026-02-10 | Sachs David C. | Chief Financial Officer | Option exercise | 82,236 | $0.00 |
| 2026-02-10 | Sachs David C. | Chief Financial Officer | Tax withholding | 42,643 | $6.93 |
| 2026-02-10 | LAUER REGAN J | Chief Accounting Officer | Option exercise | 5,482 | $0.00 |
| 2026-02-10 | LAUER REGAN J | Chief Accounting Officer | Tax withholding | 2,257 | $6.93 |
| 2026-02-10 | Adcock Richard | CEO & President | Option exercise | 274,122 | $0.00 |
| 2026-02-10 | Adcock Richard | CEO & President | Tax withholding | 140,048 | $6.93 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 8-K | 2026-10-14 | View on SEC.gov → |
| 2026-10-06 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-02 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about IBRX (ImmunityBio, Inc.). Links open the publisher — we don’t host full articles.
-
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
Yahoo · 2026-10-21 -
ImmunityBio, Inc. (IBRX) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-21 -
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
Yahoo · 2026-10-21 -
ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC
Benzinga · 2026-10-21 -
ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC
Benzinga · 2026-10-21 -
ImmunityBio, Inc. (IBRX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
ImmunityBio reports 84 percent cystectomy avoidance. Six analysts rate ImmunityBio stock Buy
AD HOC NEWS · 2026-10-20 -
9 Health Care Stocks Whale Activity In Today’s Session
Benzinga · 2026-10-20
No headlines in this category right now — try “All”.